Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Future Growth Projections For The Respiratory Syncytial Virus (RSV) Therapeutics Market Size?
The market of therapeutics for the respiratory syncytial virus (rsv) has witnessed a significant expansion in the preceding years. This market is anticipated to surge from $1.6 billion in 2024 to $2 billion in 2025, reflecting a compound annual growth rate (CAGR) of 24.6%. Factors such as rising awareness about the disease, progress in virology, susceptibility in children, epidemic breakouts, and advancements in vaccine development are accountable for the growth during the historic period.
Anticipated to experience significant expansion in upcoming years, the therapeutics market for respiratory syncytial virus (RSV) is projected to reach a value of $4.58 billion by 2029, with a compound annual growth rate (CAGR) of 23.1%. This growth during the forecast period is largely because of advancements in biologic therapies, the development of new antivirals, increased attention to the elderly population, strategies for maternal immunization, and collaborative global research. Major advancements to look forward to in this period encompass progress in monoclonal antibodies, developments in nasal vaccines and delivery systems, combination therapies, new drug delivery systems, and options for home-based treatments.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp
Which Demand Drivers Are Strengthening The Respiratory Syncytial Virus (RSV) Therapeutics Market?
The escalation in cases of RSV infection signifies the expansion of the Respiratory Syncytial Virus (RSV) therapeutics market. This highly common respiratory ailment ranges from the moderate to the severely infectious, particularly impacting newborns, young children, elderly individuals, and those with compromised immunity. The surge in RSV infections necessitates the formulation of novel treatments to suffice the growing need and minimize the severity of complications related to RSV. For instance, the Centres for Disease Control and Prevention, a US-based national public health organization, reported in September 2023 that there was a remarkable surge in hospitalizations associated with RSV among children aged under 4 years. The rate soared from 2.0 hospitalizations per 100,000 population around the week ending on August 5, 2023, to 7.0 hospitalizations per 100,000 population by August 19, 2023. Thus, the mounting prevalence of RSV infection fuels the expansion of the Respiratory Syncytial Virus (RSV) therapeutics market.
What Segmentation Insights Are Provided In The Respiratory Syncytial Virus (RSV) Therapeutics Market Research?
The respiratory syncytial virus (rsv) therapeuticsmarket covered in this report is segmented –
1) By Drug: Palivizumab; Ribavirin; Other Drugs
2) By Treatment: Immune Prophylaxis; Supportive Care; Antiviral Medications
3) By Dosage Form: Oral; Injectable; Other Dosage Forms
4) By Patient Type: Pediatrics; Adults
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Palivizumab: Monoclonal Antibody
2) By Ribavirin: Antiviral Medication
3) By Other Drugs: Cidofovir; Nitazoxanide; Other Experimental Or Off-Label Treatments
Which Notable Trends Are Transforming The Respiratory Syncytial Virus (RSV) Therapeutics Market Outlook?
A significant trend gaining traction in the respiratory syncytial virus (RSV) therapeutics market is the development of novel drugs and vaccines with improved efficacy. To consolidate their market position, major players in the respiratory syncytial virus (RSV) therapeutics market are focusing on the creation of new drugs and vaccines. For example, in May 2023, Pfizer Inc., a pharmaceutical manufacturer based in the US, secured approval from the US-based public health protection and promotion agency, the Food and Drug Administration, for ABRYSVO. This bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO (Respiratory Syncytial Virus Vaccine), is used to prevent RSV-caused lower respiratory tract illness in individuals aged 60 and above. ABRYSVO, a vaccine made from two preF proteins specifically designed to amplify immunity to RSV A and B types, has been clinically validated for safety and effectiveness.
Which Firms Are Driving Innovation Within The Respiratory Syncytial Virus (RSV) Therapeutics Market?
Major companies operating in the respiratory syncytial virus (RSV) therapeutics market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Regeneron Pharmaceuticals Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd
Access The Complete Report Here:
Which Regional Markets Are Emerging As Key Hubs For The Respiratory Syncytial Virus (RSV) Therapeutics Market?
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (RSV) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12601&type=smp
Browse Through More Reports Similar to the Global Respiratory Syncytial Virus (RSV) Therapeutics Market 2025, By The Business Research Company
Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025
Respiratory Disposables Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
Respiratory Devices And Equipment Therapeutic Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model